Occupier

Find Out The Latest

Keep in touch with news and developments from The Oxford Science Park and its occupiers here.

You can also follow us on LinkedIn

Oxford Science Park cancer experts honoured at inaugural Cancer Vaccine Awards

02 Jul 2025

Two prominent cancer experts based at The Oxford Science Park have been recognised at the UK’s first-ever Cancer Vaccine Awards Ceremony, which celebrated outstanding contributions to cancer vaccine science and clinical innovation across the country. Professor Lindy Durrant, founder and CSO of Scancell, which is headquartered at The Oxford Science Park, received the Innovation in Cancer Vaccine Development award. Her pioneering breakthroughs... Read more

Exscientia and Recursion Enter Definitive Agreement

13 Aug 2024

Recursion and Exscientia plc have announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology-enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology-driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster. Chris Gibson, Co-Founder and CEO of Recursion as well as... Read more

Evox Therapeutics Acquires Exosome AAV Technology and Intellectual Property

20 Jun 2023

IP bolsters Company’s already dominant and broad position with respect to exosome therapeutics Acquisition is in line with long-term strategy to improve exosome-mediated delivery to enable novel gene therapies and gene editors OXFORD, United Kingdom, June 20, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, has purchased Codiak Biosciences engEx-AAV™ technology platform,... Read more

Professor Tom Brown is winner of the RSC's 2023 Chemistry Biology Interface open Prize: Khorana Prize

14 Jun 2023

Professor Tom Brown is winner of the RSC's 2023 Chemistry Biology Interface open Prize: Khorana Prize Professor Tom Brown CChem FRSC of the University of Oxford has been awarded a research and innovation prize by the Royal Society of Chemistry for his major contributions in the nucleic acid field, including the synthesis of biocompatible artificial DNA, and molecular tools for genetic analysis and diagnostics. In addition to his academic... Read more

OXFORD NANOPORE TECHNOLOGIES PLC - National German rare disease study

12 Jun 2023

National German rare disease study Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, today announces a research collaboration agreement with the 'Clinical Long-read Genome Initiative' (lonGER), a new national German programme developed to evaluate the clinical and research applications of comprehensive nanopore-based sequencing to advance... Read more

News